Related references
Note: Only part of the references are listed.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
M. T. Tetzlaff et al.
ANNALS OF ONCOLOGY (2018)
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies
Emily Z. Keung et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Ana Costa et al.
CANCER CELL (2018)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Wanqiang Sheng et al.
CELL (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Unconventional T Cell Targets for Cancer Immunotherapy
Dale I. Godfrey et al.
IMMUNITY (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
Yu-Lin Su et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
被撤回的出版物: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms (Retracted article. See vol. 132, 2022)
Xian-Yang Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
The gut microbiota influences anticancer immunosurveillance and general health
Bertrand Routy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Laurence Zitvogel et al.
SCIENCE (2018)
A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment
Ameet A. Chimote et al.
SCIENCE SIGNALING (2018)
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade
Natalie J. Neubert et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Scott J. Rodig et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Chung-Han Lee et al.
TRENDS IN IMMUNOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment
Ameet A. Chimote et al.
SCIENCE SIGNALING (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming et al.
FRONTIERS IN IMMUNOLOGY (2018)
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis
Heidi Harjunpaa et al.
ONCOIMMUNOLOGY (2018)
Lynch syndrome premalignancy upregulates immune checkpoints independently from neoantigen and mutational rates
Kyle Chang
CANCER RESEARCH (2018)
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Rachel Marty et al.
CELL (2018)
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
Julie M. Collins et al.
EXPERT REVIEW OF VACCINES (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto et al.
NATURE (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Evolution of Metastases in Space and Time under Immune Selection
Mihaela Angelova et al.
CELL (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Tumor immune evasion arises through loss of TNF sensitivity
Conor J. Kearney et al.
SCIENCE IMMUNOLOGY (2018)
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation
Yusuke Shono et al.
NATURE REVIEWS CANCER (2018)
Integrating oncolytic viruses in combination cancer immunotherapy
Praveen K. Bommareddy et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
Nicole Glodde et al.
IMMUNITY (2017)
Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine
Corey Smith et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Future cancer research priorities in the USA: a Lancet Oncology Commission
Elizabeth M. Jaffee et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T. Manguso et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting
Kazuyoshi Takeda et al.
NATURE COMMUNICATIONS (2017)
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Martin Lauss et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
Yu-Pei Chen et al.
THERANOSTICS (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Rajeev K. Shrimali et al.
CANCER IMMUNOLOGY RESEARCH (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Targeting immunosuppressive adenosine in cancer
D. Vijayan et al.
NATURE REVIEWS CANCER (2017)
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors
Anna Johansson-Percival et al.
NATURE IMMUNOLOGY (2017)
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors
Vinit Kumar et al.
CANCER CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors
Anna Mondino et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion et al.
CLINICAL CANCER RESEARCH (2017)
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities
Marcin Kortylewski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
A data driven approach to predicting tissue-specific adverse events
Kaitlyn M. Gayvert et al.
CANCER RESEARCH (2017)
Precancer Atlas to Drive Precision Prevention Trials
Avrum Spira et al.
CANCER RESEARCH (2017)
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Kristin G. Anderson et al.
CANCER CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H. I. Andtbacka et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Arabella Young et al.
CANCER CELL (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
RANKL/RANK control Brca1 mutation-driven mammary tumors
Verena Sigl et al.
CELL RESEARCH (2016)
TGF-beta in tolerance, development and regulation of immunity
Chris J. C. Johnston et al.
CELLULAR IMMUNOLOGY (2016)
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai et al.
CLINICAL CANCER RESEARCH (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells
Kyle K. Payne et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Emma Nolan et al.
NATURE MEDICINE (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
Yin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Stephen J. Blake et al.
CANCER DISCOVERY (2016)
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma
Isabel Poschke et al.
ONCOIMMUNOLOGY (2016)
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Thomas Condamine et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Excluding T Cells: Is β-Catenin the Full Story?
Siwen Hu-Lieskovan et al.
CANCER CELL (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy
Chien-Chung Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
From mice to humans: developments in cancer immunoediting
Michele W. L. Teng et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment
Thomas F. Gajewski
SEMINARS IN ONCOLOGY (2015)
Intratumoral LIGHT Restores Pericyte Contractile Properties and Vessel Integrity
Anna Johansson-Percival et al.
CELL REPORTS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Yong Wha Moon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
E. C. M. Zeestraten et al.
BRITISH JOURNAL OF CANCER (2014)
The Inherent Premise of Immunotherapy for Cancer Dormancy
Masoud H. Manjili
CANCER RESEARCH (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
Fausto Petrelli et al.
EUROPEAN UROLOGY (2014)
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
Fei Duan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors
Barbara Seliger
JOURNAL OF IMMUNOTOXICOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients
Bernhard Mlecnik et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
Interactions between HLA-G and HLA-E in physiological and pathological conditions
Fabio Morandi et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mechanisms of disseminated cancer cell dormancy: an awakening field
Maria Soledad Sosa et al.
NATURE REVIEWS CANCER (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
Elena Garcia-Martinez et al.
BREAST CANCER RESEARCH (2014)
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2013)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Tumour-associated macrophages and cancer
Jenny Cook et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes
Patrick Guirnalda et al.
ONCOIMMUNOLOGY (2013)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy
Corey Smith et al.
CANCER RESEARCH (2012)
Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer
In Ja Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Hirokazu Matsushita et al.
NATURE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes
Marloes Gooden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity
Cristina Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Mechanisms of HBV-related hepatocarcinogenesis
Christine Neuveut et al.
JOURNAL OF HEPATOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Why are tumour blood vessels abnormal and why is it important to know?
J. A. Nagy et al.
BRITISH JOURNAL OF CANCER (2009)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Franck Pages et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Viruses associated with human cancer
Margaret E. McLaughlin-Drubin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2008)
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity
Vivian Goodell et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
M. Campoli et al.
ONCOGENE (2008)
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses
Maciej Kmieciak et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
J. D. Lickliter et al.
BRITISH JOURNAL OF CANCER (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Interferon-gamma and cancer immunoediting
GP Dunn et al.
IMMUNOLOGIC RESEARCH (2005)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Human papillomavirus and cervical cancer
EM Burd
CLINICAL MICROBIOLOGY REVIEWS (2003)
Share Paper
